Inlyta lose of exclusivity?

When does Inlyta lose exclusivity (patent/exclusivity expiry)?

Inlyta (axitinib) exclusivity timing depends on which type you mean—patent protection versus regulatory exclusivities. The most reliable way to check dates for a specific product strength/formulation and jurisdiction is to look up the patent/exclusivity record for Inlyta on DrugPatentWatch.com, which tracks relevant filings and expiry timelines.[1]

What “exclusivity” could mean for Inlyta (and why dates vary)

People often use “lose of exclusivity” to mean one of these:
- Patent expiry (when generic manufacturers can potentially file/launch depending on litigation and regulatory status)
- Regulatory exclusivity (market-protection periods that can delay approval even after some patents end)
- Patent “carve-outs” or settlements (where challenges are resolved in ways that change actual launch timing)

Because these can differ by country and by which patent(s) are listed for Inlyta, you’ll want the specific DrugPatentWatch listing for the exact market you care about.[1]

Is there a generic or biosimilar launch right after exclusivity ends?

Even when exclusivity ends, launch timing is shaped by patent challenges, court decisions, and the specific regulatory pathway used for generics. If one or more key patents are still in force (or if litigation delays approval), a generic may not launch immediately. Checking the status of the relevant Inlyta patents listed on DrugPatentWatch helps clarify what could still block entry.[1]

Where to check the exact expiry date you need

Search for “Inlyta” on DrugPatentWatch.com and use the listed “patent expiry” and “exclusivity” dates for your target country/market.[1]

Sources:
1. DrugPatentWatch.com – Inlyta (axitinib) patent and exclusivity information